GlobeNewswire

3D Systems Begins Shipping 3DXpert Software with Direct Metal Printers to Drive Substantial Productivity Gains and Operational Savings

Dela
  • Customer reports productivity gains of 40 percent or higher and reduction in print processing time of up to 75 percent
  • New 3DXpert Build Simulation module increases operational savings

PITTSBURGH, May 08, 2017 (GLOBE NEWSWIRE) -- 3D Systems (NYSE:DDD) today announced the immediate bundling of its innovative 3DXpert(TM) software with all of its direct metal printers to streamline precision metal workflows for customers across applications and industries. The company also announced that 3DXpert is planned to include a new Build Simulation module that allows users to accurately verify and optimize their parts, designs and supports to uncover costly issues before sending parts to print.

Photos accompanying this announcement are available at http://www.globenewswire.com/NewsRoom/AttachmentNg/70ddbdb0-6df3-4712-a85f-e03fb2119e0a

http://www.globenewswire.com/NewsRoom/AttachmentNg/9901d429-0f29-4e18-a23d-79f6f424b170

The company's 3DXpert all-in-one software solution saves users significant time and money by eliminating the need for multiple software packages, while also delivering advanced and unique capabilities in print preparation, supports and structure optimization, slicing and post-processing.

Metal Technology Inc. (MTI), specializing in custom parts for aerospace, defense and medical applications, reduced print processing times by up to 75 percent and achieved productivity gains of 40 percent or higher using 3DXpert software and 3D Systems' ProX® DMP 320. 
"One of the main drivers for us to switch over to 3DXpert was that we can compress our workflow into a single solution," said Jason Stitzel, Director of Engineering, MTI. "We went from using at least three different software systems to get the final product to doing it all with one. 3DXpert removes the need to convert from a solid model to an STL, a process that inherently introduces issues and errors."

"Before we used 3DXpert, running a complicated part through a slicing engine took close to 20 hours to process, slice, run the parameters and create a build file. With 3DXpert, we could do the same build file in just four hours," Stitzel added.

For more details on MTI's experience with 3DXpert, click here.

Using 3DXpert's unique capabilities, customers will be able to increase productivity and lower cost of operations by:

  • Eliminating the need to convert files into mesh while improving data quality and integrity with the ability to natively work with CAD data (solid & surfaces/b-rep);
  • Easily making changes at any stage using history based parametric CAD tools by working in a hybrid (Mesh, Solid and Lattice) modeling environment;
  • Accelerating print time while maintaining part integrity using the  patent-pending 3D Zoning capability , that allows customers to easily assign different print strategies to different areas of a part based on geometry features, and seamlessly merge them into a single scan-path;
  • Minimizing part weight and material with lightning-fast creation and editing of micro lattices using structure optimization tools;
  • Generating optimal scan-paths with unique printing strategies that take into account the design intent and part geometry; and
  • Programming post-processing operations (e.g. drilling and milling) in the same software with no need to transfer data to a separate software.

"3DXpert is a real game changer for customers," said Ilan Erez, Senior Vice President, General Manager, Software, 3D Systems. "It's enabling customers to print high-quality, complex metal parts more efficiently and at a lower total cost of operation, all in one integrated software solution."

The new Build Simulation functionality helps customers avoid expensive trial and error iterations typically involved in validating designs, minimize build failures, reduce production time and prevent potential printer damage. 3DXpert's Build Simulation is planned for availability second half of 2017.

3D Systems will preview the new Build Simulation module of 3DXpert along with its entire range of end-to-end manufacturing solutions for aerospace, automotive, healthcare, dental, durable goods and entertainment at the RAPID + TCT 2017 trade show in Pittsburgh, PA, May 9-11, booth 2525.

More information on these solutions can be found at www.3dsystems.com.

Forward-Looking Statements
Certain statements made in this release that are not statements of historical or current facts are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995.  Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of the company to be materially different from historical results or from any future results or projections expressed or implied by such forward-looking statements. In many cases, forward looking statements can be identified by terms such as "believes," "belief," "expects," "may," "will," "estimates," "intends," "anticipates" or "plans" or the negative of these terms or other comparable terminology.  Forward-looking statements are based upon management's beliefs, assumptions and current expectations and may include comments as to the company's beliefs and expectations as to future events and trends affecting its business and are necessarily subject to uncertainties, many of which are outside the control of the company.  The factors described under the headings "Forward-Looking Statements" and "Risk Factors" in the company's periodic filings with the Securities and Exchange Commission, as well as other factors, could cause actual results to differ materially from those reflected or predicted in forward-looking statements. Although management believes that the expectations reflected in the forward-looking statements are reasonable, forward-looking statements are not, and should not be relied upon as a guarantee of future performance or results, nor will they necessarily prove to be accurate indications of the times at which such performance or results will be achieved. The forward-looking statements included are made only as the date of the statement. 3D Systems undertakes no obligation to update or review any forward-looking statements made by management or on its behalf, whether as a result of future developments, subsequent events or circumstances or otherwise.

About 3D Systems  
3D Systems provides comprehensive 3D products and services, including 3D printers, print materials, on demand manufacturing services and digital design tools. Its ecosystem supports advanced applications from the product design shop to the factory floor to the operating room. 3D Systems' precision healthcare capabilities include simulation, Virtual Surgical Planning, and printing of medical and dental devices as well as patient-specific surgical instruments. As the originator of 3D printing and a shaper of future 3D solutions, 3D Systems has spent its 30 year history enabling professionals and companies to optimize their designs, transform their workflows, bring innovative products to market and drive new business models.

More information on the company is available at www.3dsystems.com

Investor Contact:

Stacey Witten
Email: investor.relations@3dsystems.com

Media Contact: 

Diane Parrish
Email: press@3dsystems.com




This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: 3D Systems Corporation via Globenewswire

Om

GlobeNewswire



Följ GlobeNewswire

Abonnera på våra pressmeddelanden.

Senaste pressmeddelandena från GlobeNewswire

Karolinska Development's portfolio company Modus Therapeutics completes enrollment in Phase II study with sevuparin7.1.2019 12:00Pressmeddelande

STOCKHOLM, January 7, 2019. Karolinska Development's portfolio company Modus Therapeutics announces that the patient enrollment has been completed in the Phase II study with sevuparin in patients with sickle cell disease (SCD). The results from the study is expected in mid 2019. Modus Therapeutic's randomized, double blind study contains 140 SCD-patients with Acute Vaso Occlusive Crisis (VOC). It compares intravenously administered sevuparin with placebo. The primary endpoint of the study is the demonstration of a reduced time to resolution of patient's VOC. Clincal sites across Europe and the Middle East took part in the study that was conducted in conjunction with Modus Therapeutics' co development partner Ergomed. SCD has a high unmet medical need as there are currently no approved therapies for VOCs. It is an inherited blood disorder that affects between 90,000 to 100,000 patients in the U.S. and is characterized by severely painful VOCs that lead to organ damage due to a lack of o

Karolinska Development's portfolio company Modus Therapeutics completes enrollment in Phase II study with sevuparin7.1.2019 12:00Pressmeddelande

STOCKHOLM, January 7, 2019. Karolinska Development's portfolio company Modus Therapeutics announces that the patient enrollment has been completed in the Phase II study with sevuparin in patients with sickle cell disease (SCD). The results from the study is expected in mid 2019. Modus Therapeutic's randomized, double blind study contains 140 SCD-patients with Acute Vaso Occlusive Crisis (VOC). It compares intravenously administered sevuparin with placebo. The primary endpoint of the study is the demonstration of a reduced time to resolution of patient's VOC. Clincal sites across Europe and the Middle East took part in the study that was conducted in conjunction with Modus Therapeutics' co development partner Ergomed. SCD has a high unmet medical need as there are currently no approved therapies for VOCs. It is an inherited blood disorder that affects between 90,000 to 100,000 patients in the U.S. and is characterized by severely painful VOCs that lead to organ damage due to a lack of o

Stillfront Group rekryterar ansvarig för M&A19.12.2018 12:07Pressmeddelande

PRESSMEDDELANDE 19 december, 2018 Stillfront Group rekryterar ansvarig för M&A Stillfront Group, en marknadsledare inom 'free to play' online strategispel, annonserar idag att Marina Andersson har utsetts till ansvarig för M&A och kommer att ingå i koncernledningen. Marina har närmare tjugo års erfarenhet från investment banking och M&A. Hon har omfattande erfarenhet inom strategisk och finansiell rådgivning, affärsgenerering, projektledning inom förvärv och försäljningar av företag, finansiell analys, due diligence, samt företagsvärdering. Tidigare positioner inkluderar: Director, Deloitte's Corporate Finance Advisory team, Director, ICECAPITAL Securities, Associate Partner och Investment Manager, Deseven, samt M&A Analytiker på Carnegie. Marina har två magister-examen från Stockholms universitet och Russian Herzen State Pedagogical University. "Förvärv är en viktig del av Stillfronts affärsstrategi och vi är mycket glada att rekrytera Marina Andersson. Marinas breda erfarenhet och pr

Stillfront Group announces Head of M&A19.12.2018 12:07Pressmeddelande

PRESS RELEASE December 19, 2018 Stillfront Group announces Head of M&A Stillfront Group, a market leader in 'free to play' online strategy games, today announces that Marina Andersson has been appointed as Head of M&A and will be part of the Group's management team. Marina has close to 20 years track record of investment banking and M&A. She has extensive competence within strategic and financial advisory, deal generation, buy and sell side M&A project management, financial analysis, due diligence and company valuation. Former positions include: Director at Deloitte's Corporate Finance Advisory team, Director at ICECAPITAL Securities, Associate Partner and Investment Manager at Deseven, M&A Analyst at Carnegie. She holds two Master degrees from Stockholm University and Russian Herzen State Pedagogical University. "Acquisitions are a crucial part of Stillfront's business strategy and we are very pleased with the appointment of Marina Andersson. Marina's breadth of experience and profess

Oboya tecknar ett samarbetsavtal med Gaia avseende biomaterial13.12.2018 11:41Pressmeddelande

Oboya Horticulture Industries AB (publ) ("Oboya") har tecknat ett viktigt och långsiktigt samarbetsavtal avseende miljövänligt biomaterial med Gaia Biomaterials AB ("Gaia") i Helsingborg, Sverige. Avtalet innebär att Oboya använder Gaias biomaterial för tillverkning och utveckling av miljövänliga odlingsprodukter till odlingsindustrin. Oboya har under de senaste åren arbetat aktivt med innovation, miljö- och hållbarhetsfrågor och vårt mål är att främja miljö och hållbarhet inom odlingsindustrin genom att erbjuda miljövänliga odlingsprodukter till våra kunder. Oboya anser att användningen av biomaterial kommer att vara viktigt för framgång i omställningen till en fossilfri odlingsindustri världen över. Samarbetsavtalet innebär att Oboya använder Gaias biomaterial i sin produktion och att vi genom Gaias kompetens kan utveckla nya miljövänliga odlingsprodukter. Gaias biomaterial är biologiskt nedbrytbart, komposterbart samt ger upp till 80 % lägre koldioxidutsläpp vid förbränning jämfört

Oboya signs a cooperation agreement with Gaia regarding biomaterials13.12.2018 11:41Pressmeddelande

Oboya Horticulture Industries AB (publ) ("Oboya") has signed an important and long-term cooperation agreement on environmentally friendly biomaterials with Gaia Biomaterials AB ("Gaia") in Helsingborg, Sweden. The agreement means that Oboya uses Gaias biomaterials for the production and development of environmentally friendly cultivation products for the cultivation industry. Oboya has been actively involved in innovation, environmental and sustainability issues in recent years, and our goal is to encourage environmental and sustainability in the cultivation industry by offering environmentally friendly cultivation products to our customers. Oboya believes that the use of biomaterials will be important for success in the conversion to a fossil-free cultivation industry worldwide. The cooperation agreement means that Oboya uses Gaias biomaterials in its production and that through Gaias expertise we can develop new environmentally friendly cultivation products. Gaias biomaterials are bi

I vårt pressrum kan du läsa de senaste pressmeddelandena, få tillgång till pressmaterial och hitta kontaktinformation.

Besök vårt pressrum